GRAMD1C

Across TCGA pan-cancer cohorts, GRAMD1C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GRAMD1C data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GRAMD1C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GRAMD1C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and ESCA are the cancer types where GRAMD1C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.186	0.684	<.001	48	view →
UCEC	DFS	Median	All	0.920	0.621	.015	14	view →
ESCA	OS	Median	II,III,IV	0.248	0.686	.019	9	view →
BLCA	OS	Median	IV	0.132	0.599	.004	6	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GRAMD1C–HNSC (DFS)

Open the HNSC breakdown →